Rare Disease
In progressive MS, myelin continually degrades leading to axon degeneration and neuronal death. Neurodegeneration is responsible for chronic disability and MS progression.
Unmet need: No regenerative or remyelinating therapies currently approved. Current treatments are based on immunosuppression with little action, if any, on neuroprotection: progressive forms are hardly treated.
Our approach: EGF promotes oligodendrocyte maturation and myelin repair, while xB3 ensures targeted CNS delivery.
Potential impact: A regenerative and anti-inflammatory treatment in progressive MS could dramatically shift the therapeutic landscape.
Regulatory path: Strong potential for orphan drug designation (ODD) and fast- track approval strategies
